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ABSTRACT
Gene regulatory interactions underlying the early
stages of non-genotoxic carcinogenesis are poorly
understood. Here, we have identified key candidate
regulators of phenobarbital (PB)-mediated mouse
liver tumorigenesis, a well-characterized model of
non-genotoxic carcinogenesis, by applying a new
computational modeling approach to a comprehen-
sive collection of in vivo gene expression studies.
We have combined our previously developed motif
activity response analysis (MARA), which models
gene expression patterns in terms of computation-
ally predicted transcription factor binding sites with
singular value decomposition (SVD) of the inferred
motif activities, to disentangle the roles that
different transcriptional regulators play in specific
biological pathways of tumor promotion.
Furthermore, transgenic mouse models enabled us
to identify which of these regulatory activities was
downstream of constitutive androstane receptor
and b-catenin signaling, both crucial components
of PB-mediated liver tumorigenesis. We propose
novel roles for E2F and ZFP161 in PB-mediated hep-
atocyte proliferation and suggest that PB-mediated
suppression of ESR1 activity contributes to the de-
velopment of a tumor-prone environment. Our study
shows that combining MARA with SVD allows for
automated identification of independent transcrip-
tion regulatory programs within a complex in vivo
tissue environment and provides novel mechanistic
insights into PB-mediated hepatocarcinogenesis.
INTRODUCTION
Aberrant activity of transcription factors (TFs) is a hallmark
of both human (1–3) and mouse (4) hepatocarcinogenesis
and is considered as a key intrinsic regulatory mechanism
underlying epigenetic reprograming associated with cancer
development (5). Non-genotoxic carcinogens (NGC) are a
group of compounds that do not directly affect DNA (6),
but that produce perturbations in the gene expression and
epigenetic state of cells (7–9) which, if given in sufﬁcient
concentration and duration, facilitate tumor formation, typ-
ically through the promotion of pre-existing neoplastic cells
into neoplasms (10,11). However, little is known about the
regulatory mechanisms that underly the tumor promotion
byNGC, particularly regarding the early regulatory changes
in response to the carcinogen.
The anticonvulsant phenobarbital (PB) is a well-estab-
lished rodent NGC that has been extensively used to in-
vestigate the promotion of liver tumors (12–14). PB
accomplishes its diverse effects on liver function, at least
in part, by promoting nuclear translocation of the consti-
tutive androstane receptor (CAR) (15) through inhibition
of Epidermal Growth Factor Receptor (EGFR) signaling
(16). CAR activation is required for the acute and the
chronic response to PB treatment and for liver tumor for-
mation elicited upon prolonged PB treatment (17–21). In
addition to this crucial role of CAR, when liver tumors are
promoted through PB treatment in combination with an
initial treatment with diethylnitrosamine (DEN), >80% of
the resulting tumors harbor activating mutations in b-
catenin (22) that stabilize b-catenin, leading to enhanced
nuclear translocation and subsequent target gene activa-
tion (23–27).
Apart from the crucial roles for CAR and b-catenin in
PB-mediated liver tumor promotion, little is known about
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additional transcriptional regulators that orchestrate the
complex and dynamic PB-mediated gene expression
programs associated with early molecular responses to
PB treatment (28) and long-term PB tumorigenic effects
(12–14).
In this study, we have elucidated gene regulatory inter-
actions underlying dynamic PB-mediated transcriptional
responses during the early stages of liver non-genotoxic
carcinogenesis by integrating multiple gene expression
datasets from independent in vivo mouse PB studies. Our
primary dataset consists of an early kinetic study (seven
time points across 91 days of PB treatment) originally
designed to investigate the temporal sequence of molecu-
lar and histopathological perturbations during the early
stages of PB-mediated liver tumor promotion in vivo
(9, 28). Several challenges are associated with the extrac-
tion of key gene regulatory interactions from gene expres-
sion time course data. First, we needed to identify the
relative contributions (activities) of speciﬁc transcriptional
regulators underlying the observed genome-wide gene ex-
pression changes. This was achieved using our recently
developed motif activity response analysis [MARA,
(29)]. MARA capitalizes on sophisticated computational
methods, developed over the last decade (30), that allow
comprehensive prediction of binding sites for hundreds of
mammalian TFs across all mammalian promoters (31).
Using such computational predictions, MARA models
observed gene expression patterns explicitly in terms of
the predicted regulatory sites and uses this to infer the
regulatory activities of TFs. A number of recent studies
(32–43) demonstrate that this approach can successfully
identify key regulators ab initio across different model
systems of interest.
A second challenge was to disentangle the complex
range of PB-mediated gene expression programs in
mouse liver tissue that are associated with distinct biolo-
gical events including xenobiotic responses, tumor promo-
tion and tumorigenesis.
Here, we show that combining MARA with singular
value decomposition (SVD) allows for automated
disentangling of independent transcription regulatory
programs within a complex in vivo tissue environment.
We were able to successfully infer key gene regulatory
proteins for xenobiotic responses, tumor promotion and
end-stage tumors as well as assess their genetic dependence
on CAR and b-catenin signaling pathways.
Collectively, our analyses provide novel mechanistic
insights into PB-mediated tumor promotion in the mouse
liver, including a proposed role of E2F and ZFP161 in
regulating PB-mediated hepatocyte proliferation at both
early and tumor stages and progressive PB-mediated sup-
pression of ESR1 activity that likely contributes to the
development of a tumor-prone environment.
MATERIALS AND METHODS
Gene expression datasets and Affymetrix
GeneChip processing
A library of 109 genome-wide messenger RNA (mRNA)
expression patterns was compiled from four different
studies (Figure 1a). In all four studies gene expression
was proﬁled using Affymetrix GeneChip MOE-4302
(Affymetrix, Santa Clara, CA, USA). The analysis of the
micro-array data was done with the R statistical package,
version 2.13 (2005) and Bioconductor libraries, version
1.4.7 (44).
From gene expression matrices to motif activity matrices
Matrices of activities for 189 mammalian regulatory
motifs across all samples were inferred from the
RMA-normalized expression matrices using the MARA
algorithm (29) (Figure 1b and c). MARA models
genome-wide gene expression patterns in terms of pre-
dicted functional Transcription Factor Binding Sites
(TFBSs) within proximal promoter regions (running
from 300 to+100 relative to transcription start) of the
40 300 promoters. The model assumes that the expression
eps of a promoter p in sample s is a linear function of the
predicted numbers of binding sites Npm for each motif m in
promoter p and the (unknown) activities Ams of each of
the motifs m in sample s, i.e.
eps ¼ ~cs+cp+
X
m
NpmAms
where cp reﬂects the basal activity of promoter p and ~cs is a
normalization constant corresponding to the total expres-
sion in sample s. The activities Ams, as well as error bars
Ams on these activities, are thus inferred from the
measured expression data eps and the predicted binding
sites Npm. The number of functional TFBSs Npm was pre-
dicted using the Bayesian regulatory site prediction algo-
rithm MotEvo, which incorporates information from
orthologous sequences in six other mammals and uses
explicit models for the evolution of regulatory sites (30).
The 189 regulatory motifs represent binding speciﬁcities of
roughly 350 different mouse TFs. Besides the motif
activities, MARA also calculates a z-score quantifying
the signiﬁcance of each motif in explaining the observed
expression variation across the samples, the target genes of
each motif, and the sites on the genome through which the
regulators act on their targets.
Formally, the activity Ams corresponds to the amount
by which the expression eps would be reduced if a binding
site for motif m in promoter p were to be removed. Thus,
an increasing activity is inferred when its targets show on
average an increase in expression, that cannot be ex-
plained by the presence of other motifs in their promoters.
The details of the method are described elsewhere (29). An
overview of the analysis strategy and an outline of the
MARA approach are depicted in Figure 1.
Detection of differential motif activity between pairs
of conditions
We quantiﬁed the differential motif activity between two
conditions using a z-statistic as
zmc ¼
Amc1  Amc2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A2mc1+A
2
mc2
q
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where Amc is the averaged motif activity proﬁle over rep-
licates for condition c and motif m and Amc is the stand-
ard error on the corresponding motif activity, which is
computed using a rigorous Bayesian procedure
(Balwierz, PJ. et al, manuscript under review). The z-
values quantify the evidence for a change in regulatory
activity of the motif between the two conditions. That is,
if zmc is highly positive it indicates that predicted targets
of motif m are upregulated in condition c1 relative to con-
dition c2, in a way that cannot be explained by the
activities of other regulators. We consider motifs differen-
tially active if jzj  1:5.
In order to avoid any confounding batch effects, we
only calculate differential activities across conditions
from the same dataset. Comparing activities between
treated and control samples at different timepoints of
the kinetic study allowed for the identiﬁcation of PB-
mediated dysregulated TFs at the early stage of PB treat-
ment. Comparison of activities between wild-type (WT)
and CAR/b-catenin null in physiological conditions, i.e.
without treatment, identiﬁed motifs whose activities are
modulated upon KO of the respective TF (Figure 2a
and c). We consider such motifs to be downstream of
the b-catenin/CAR pathways in physiological conditions.
Similarly, comparison of activities between PB-treated
and non-treated samples allowed for the identiﬁcation of
motifs that are dysregulated by PB treatment. By further
comparing the changes in motif activities upon PB treat-
ment for both WT and CAR-null samples, we can identify
motifs dysregulated by PB in a manner that is independent
of CAR signaling and motifs whose dysregulation is
downstream of CAR (Figure 2a and c). Comparison of
activities between promoted tumors and surrounding PB-
treated tissue identiﬁed motifs dysregulated in promoted
tumors; comparison of activities between non-promoted
tumors and surrounding non-treated tissue identiﬁed
motifs dysregulated in liver tumors irrespective of PB
treatment. Motifs uniquely dysregulated in promoted
tumors were classiﬁed as promoted tumor-speciﬁc regula-
tors (Figure 2b).
Characterization of PB-mediated early motif
activity proﬁles
SVD of the motif activities
We performed SVD of the activities of the 189 motifs
across the seven timepoints in PB- and vehicle-treated
livers, i.e. a matrix A containing 189 rows and 14
columns. SVD resulted in a decomposition, A ¼ UV,
where  is a diagonal matrix containing the singular
values, U and V contain the orthonormal bases deﬁned
by right and left singular vectors of A, respectively. Each
motif activity proﬁle ~am with ð~amÞs ¼ Ams can be thought
of as a linear combination of the right singular vectors
f~vkg.
Visualization and interpretation of the SVD results
To visualize the right singular vectors f~vkg, we plotted the
activities vks on the vertical axis as a function of the time
corresponding to each sample s on the horizontal axis and
coloring all samples corresponding to PB treatment black,
and those corresponding to control-treatment gray,
e.g. Figure 1d. This visualization facilitated the biological
interpretation of the singular vectors. Biological interpret-
ation was further facilitated by identiﬁcation of the regu-
latory motifs whose activity proﬁles correlate most
strongly (either positively or negatively) with the activity
proﬁle of the singular vector.
Identiﬁcation of representative motifs of the
singular vectors
As the right singular vectors form an orthonormal basis of
the space of activity proﬁles, the projection of a given
motif activity proﬁle onto a right singular vector indicates
how strongly the motif’s activity proﬁle overlaps with the
basis vector speciﬁed by the singular vector. The projec-
tions of the motif activity proﬁles ~am onto right singular
vectors ~vk are calculated as qmk ¼ ~am  ~vk and these values
are readily obtained from the SVD results as AV ¼ U
such that qmk ¼ ðUÞmk.
We additionally computed Pearson correlations
between the motif activity proﬁles ~am and the right
singular vectors ~vk. As the vectors ~vk are linear combin-
ations of the motif activity proﬁles ~am that are mean
centered, i.e.
P
s ams ¼ 0, these are also mean centered.
Consequently, the Pearson correlation coefﬁcients can
also be readily obtained from the SVD results as
(a)
(b)
(c)
Figure 2. Schematic representation of contrasts applied for differential
motif activity analysis of each dataset. The color of the dot indicates
whether the sample is WT (black), b-catenin KO (green), CAR KO
(red) or tumor (blue). White boxes correspond to control samples
and gray boxes to PB-treated samples. The arrows show which pairs
of samples are compared for each contrast and point to corresponding
rows with example motif activity changes (blue corresponding to
downregulation z < 1:5, pink to upregulation z > 1:5 and white no
signiﬁcant change jzj < 1:5). (a) Motif activities from the CAR KO
study are compared to identify regulators downstream of the CAR
pathway under physiological conditions and under PB treatment.
(b) Motif activities from the tumor study are compared to identify
promoted tumor-speciﬁc regulators. (c) Motif activities from
the b-catenin KO study are compared to identify downstream regula-
tors of the b-catenin pathway under physiological conditions.
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mk ¼ qmk=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
k0 ðqmk0 Þ2
q
. As the activity proﬁles of differ-
ent motifs have different overall ‘lengths’, the projections
and Pearson correlations do not carry identical informa-
tion. Motifs with large activities tend to have high
absolute projections with a given singular vector, even if
the motif activity proﬁle is not similar to the activity
proﬁle of the singular vector. In contrast, a motif with
small activities will tend to have low projections, but
may have a high correlation with a given singular vector.
In order to identify representative motifs for each
singular vector, motifs were ranked according to both pro-
jection and correlation scores. The highest (most positive
scores in both projection and correlation) and lowest
(most negative scores in both correlation and projection)
motifs were selected for each singular vector. As some
degree of redundancy is present among regulatory
motifs, we further reﬁned our motifs selection in a system-
atic manner following criteria that are detailed in the
‘Results’ section.
Gene Ontology enrichment analysis
The DAVID Bioinformatics Resource (Database for
Annotation, Visualization and Integrated Discovery)
(45,46), version 6.7, sponsored by the National Institute
of Allergy and Infectious Diseases (NIAID), NIH, was
used to investigate the statistical enrichment of biological
terms and processes associated with the predicted target
genes of each motif of interest. We directly imported
ofﬁcial gene symbols into DAVID, exported enrichment
from biological pathways from Gene Ontology and Kyoto
Encyclopedia of Genes and Genomes (KEGG), ﬁltered
out redundant terms and selected biological processes
with P-value of enrichment <0.05.
RESULTS
Overview of liver toxicogenomic data from
phenobarbital-treated mouse models
In order to investigate gene regulatory networks underlying
early PB-mediated liver tumor promotion, we used four
transcriptomic datasets which are illustrated in Figure 1a.
Our primary dataset is composed of transcriptome
proﬁling data from a PB kinetic study in B6C3F1 (livers
from vehicle, i.e. control and PB-treated male mice at+1,
+3, +7, +14, +28, +57 and +91 days of dosing). This
dataset enabled us to investigate gene expression
dynamics during the ﬁrst 3 months of PB treatment.
A second CAR knock-out (KO) study composed of tran-
scriptome proﬁling data from livers of vehicle- and PB-
treated C3H male WT and CAR-null mice (at+161 days
of dosing) enabled us to investigate which of the responses
to PB treatment were CAR-dependent at this later time
point. A third tumor study consisting of samples from
promoted (at +35 weeks of PB treatment) and non-
promoted tumors as well as their related surrounding
tissue from C3H male mice, enabled us to identify gene
regulatory changes that were speciﬁc to promoted
tumors, as opposed to being a shared feature of tumor
tissues in general. Finally, a b-catenin KO study
composed of livers from WT and b-catenin-null C3H
male mice enabled us to investigate which of the identiﬁed
TFs were downstream of b-catenin in physiological condi-
tions. In both the CAR KO and tumor studies, mice were
DEN-initiated at 4 weeks of age.
Identifying PB-modulated activities of transcriptional
regulators using MARA
MARA is a general method for inferring the activities of a
large collection of mammalian TFs (as represented by their
DNAbinding ‘motifs’) bymodeling gene expression data in
terms of computationally predicted regulatory sites in pro-
moters. The basic approach is illustrated in Figure 1b. Note
that motif activities are inferred from the behavior of the
expression levels, typically hundreds, of predicted ‘targets’
of the motif and do not directly involve analysis of the ex-
pression levels of the regulators themselves. This is espe-
cially useful in systems where TF activities are modulated
through subcellular localization and post-translational
modiﬁcations, rather than at the transcriptional level, e.g.
such as the PB-mediated CAR nuclear translocation and
induction of downstream transcriptional responses that we
study here. Importantly, apart from inferring the motif
activities Ams, MARA also rigorously infers error bars on
these motif activities Ams, which allow to quantify to what
extent motif activities are signiﬁcantly varying across the
samples for each motif. The overall signiﬁcance of each
motif m is then represented by a z-statistic (‘Materials
and Methods’ section).
TFs underlying early PB-mediated liver
transcriptional dynamics
Figure 1d shows the activities of four motifs observed
within the time course of control and PB-treated mice,
illustrating the range of different proﬁles that can be
observed. For example, the motif bound by the family
of E2F TFs and the motif bound by AHR, ARNT and
ARNT2 TFs both showed substantial changes in activity
across the time course that are largely the same in the
control and PB-treated animals, except for E2F’s activity
at the ﬁrst timepoint. In contrast, the TATA-box motif
bound by TATA Binding Protein (TBP) exhibited almost
constant activity across time but showed a strong shift in
behavior between control and PB-treated animals. The
LMO2 motif showed no signiﬁcant activity for the ﬁrst
month of the time course but at later time points
(during the last 2 months) there was a marked divergence
between PB-treated and control animals.
SVD identiﬁes four characteristic motif activity proﬁles
underlying early PB-mediated transcriptional changes
Although it is possible to formulate biological interpret-
ations and hypotheses for observed motif activity proﬁles
on a case-by-case basis, it is unclear how this could be
performed in a systematic and unbiased manner across a
large number of motifs. This is especially challenging,
because prior biological knowledge indicates that
multiple biological processes, including completion of
postnatal liver development, acute and sustained xeno-
biotic responses to PB treatment and tumor promotion,
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are occurring in parallel in our system. To address this
problem, we applied a SVD approach to decompose the
matrix of inferred motif activities Ams from the early
kinetic study into linearly independent motif activity
proﬁles that capture most of the variation in all motif
activities.
Over 70% of the variance in the activity matrix was
explained by the ﬁrst four components of the SVD
as evidenced by the spectrum of singular values
(Figure 3b). The activity proﬁles of the ﬁrst four right
singular vectors, ~v1 through ~v4, are shown in Figure 3c.
The ﬁrst right singular vector accounted for 35% of the
variance and was characterized by an approximately
constant positive activity early in the time course that
decreased dramatically after 2 weeks. The activity proﬁle
of this ﬁrst singular vector was identical in the PB-treated
and control groups. The steep drop in activity after
2 weeks coincided with the completion of postnatal liver
development in this study, as indicated by the transcrip-
tional proﬁle of the hepatoblast marker a-fetoprotein
(Afp) (47,48) (Supplementary Figure S4). We thus
propose that this characteristic motif activity proﬁle is
associated with postnatal liver development. This conclu-
sion is supported by some of the motifs associated with
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Figure 3. Overview of the analysis strategy for identifying key regulatory activities of the early PB-mediated transcriptional dynamics. (a) SVD
factorizes the activity matrix of the early kinetic study: A ¼ U  ,  VT, with the right singular vectors ~vk giving orthonormal motif activity proﬁles
that capture most of the variation in activity proﬁles across all motifs. (b) Proportion of the variance of the motif activity matrix explained by the 10
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this singular vector (see Supplementary Data). As this
process is presumably not relevant for the process of
non-genotoxic tumor promotion, we have not further
focused on this singular vector and a characterization of
its associated regulators is presented in the Supplementary
Data.
The second singular vector accounted for 20% of the
variance and was characterized by an activity proﬁle that
is almost entirely constant with time, but that showed a
large difference between the PB-treated and vehicle-
treated samples. This singular vector thus corresponds to
a sustained xenobiotic response.
The third singular vector accounted for 10% of the
variance and was characterized by a difference in
activity between the control and treated group at Day 1
only; whereas activity in the control samples remained
approximately constant in the ﬁrst 3 days, activity was
much higher at Day 1 and dropped signiﬁcantly in PB-
treated samples over the same initial phase. Given that PB
mediates a transient mitotic response at Day 1 [also pre-
viously identiﬁed in other studies (18, 28)], we conclude
that the biological pathway corresponding to this charac-
teristic activity proﬁle is the transient PB-mediated prolif-
erative response.
Finally, the fourth singular vector accounted for 5% of
the variance and was characterized by a divergence in the
activity of the PB-treated and control groups in the last
month of the 13-week time course. Given that this is the
most signiﬁcant singular value for differences between the
PB-treated and control samples toward the end of the time
course, we infer that this characteristic adaptive xeno-
biotic response activity proﬁle might be an important con-
tributor to the progressive creation of a tumor-prone
environment.
In summary, we have shown that the behavior of regu-
latory motifs in the early stages of PB treatment are
dominated by four characteristic activity proﬁles that
account for >70% of variance of the motif activities and
which correspond to the following fundamental biological
processes: (i) the completion of postnatal liver develop-
ment, (ii) a constant xenobiotic response, (iii) a PB-
mediated acute mitogenic response and (iv) an adaptive
xenobiotic response (late response to PB treatment).
Identiﬁcation of representative motifs underlying the early
dysregulated biological pathways
To determine motifs underlying the four characteristic
motif activity proﬁles identiﬁed in the previous section,
we selected motifs which contributed and correlated the
most with each of the four singular vectors (Figure 3c, d, e
and f). In this way we obtained, for each of the four
singular vectors, two clusters of motifs with similar
activity proﬁles, i.e. one correlating negatively with the
singular vector and one correlating positively (Figure 3d
and f). The advantage of extracting clusters of the most
important regulatory motifs in this way, rather than
simply clustering the motif activity proﬁles directly, is
that many of the motif activity proﬁles contain compo-
nents associated with different biological processes that
are operating in parallel in our system. By ﬁrst using
SVD to identify the most signiﬁcant characteristic
activity proﬁles that are mutually ‘independent’, i.e. the
singular vectors, we disentangle the regulatory activities
associated with these different processes and cluster the
motifs by the biological process.
We further reﬁned the selection of the motifs associated
with each singular vector as follows: (i) removing motifs
for which the overall signiﬁcance was too low (z < 1:5
for motifs regulating postnatal liver development or the
constant xenobiotic response and under z < 1:0 for motifs
regulating the transient mitogenic response or the adaptive
xenobiotic response); (ii) removing motifs whose cognate
TFs were not expressed in the liver (log expression <6.0);
(iii) using z-scores for the differential activity per time
point between PB-treated and control samples, we
required zc  1:5 at minimum four time points out of
the seven to belong to ~v2, at Day 1 to belong to ~v3 and
at Day 91 to belong to ~v4. This lead to the identiﬁcation of
eight groups of motifs, i.e. two for each characteristic
proﬁle (Supplementary Table S1).
To further investigate the biological roles of the motifs
associated with the four singular vectors, we performed
Gene Ontology and KEGG functional enrichment
analysis of the targets of the eight groups of motifs that
are either positively or negatively associated with one
of the singular vectors (Figure 4 and Supplementary
Figure S5). Below is a brief description of most important
ﬁndings.
Constant xenobiotic response. As discussed further below,
it is well known that CAR is a crucial regulator involved
in the xenobiotic response and thus a prime candidate
for a regulator associated with a constant xenobiotic
response. Unfortunately, as there is currently no high-
quality regulatory motif available for CAR, our TFBS
predictions do not include CAR target sites and our
analysis is thus unable to infer CAR’s activity ab initio.
However, our analysis identiﬁed several additional regu-
lators that are associated with a sustained xenobiotic
response, i.e. a constant difference in activity between
the PB-treated and control samples (a full list of
associated motifs is presented in Supplementary Table S1).
Among these is TBP, whose targets are signiﬁcantly
upregulated under PB treatment and enriched in oxida-
tion-reduction processes (Figure 4a), and NFE2 whose
target genes are involved in homeostatic processes
(Figure 4b) and include the proteasome complex (e.g.
Psmc3, Ufd1l and Ube2v1) and oxidative stress genes
(e.g. Ggt1, Txn1 and Adh7). These targets represent key
pathways of the liver drug-induced response that have
been recently shown to be regulated by NFE2 in hepato-
cytes (49).
Transient proliferative response. It has been observed pre-
viously that PB treatment leads to a transient mitogenic
response (18,28,20). Our analysis revealed that the process
is positively regulated by the E2F family of TFs, whose
motif activity is signiﬁcantly increased at Day 1 upon
PB treatment (z ¼ 2:2). E2F family members are known
regulators of cell proliferation and the functions of their
predicted targets (Figure 4c) further conﬁrms their speciﬁc
role in DNA replication, DNA repair and mitosis (50–53).
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Interestingly, while eight TFs are potentially binding this
motif, three of them (E2F1, E2F2 and E2F8) display a
positive correlation between their gene expression and
the motif activity in the time course (Supplementary
Figure S3a and Supplementary Table S6), suggesting
that it may be these three TFs that are involved in the
PB-mediated transient hyperplastic response.
Our analysis predicted ZFP161 as an additional regula-
tor of the transient hyperplastic response, whose targets
are downregulated upon PB treatment. Interestingly,
ZFP161’s target genes are enriched in transcriptional re-
pressors (e.g. Rb1, Bcl6, Tle2, Klf9 and Foxp1), many of
which are known to repress the cell cycle and cell growth.
Moreover, positive regulation of cell proliferation by
ZFP161 is further supported by negative regulation
of cell death genes (Figure 4d). Together, these results
suggest that PB-mediated ZFP161 activation may lead
to the downregulation of an important group of transcrip-
tional repressors and concomitant cell cycle activation.
Progressive xenobiotic response. Finally, our analysis
identiﬁed several motifs associated with a divergence
between motif activity in the PB-treated and control
samples in the last month of the time course. Among the
downregulated motifs is ESR1, whose predicted targets
regulate extracellular matrix (ECM) genes and may thus
regulate tissue remodeling (Figure 4e). NR5A1,2 is an
additional regulator whose activity was downregulated
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after 3 months of PB treatment (Figure 4e). Interestingly,
Nr5a2 (known as liver receptor homolog-1 or LRH-1) is
an established regulator of cholesterol, bile acid homeo-
stasis, glucose and lipid metabolism (54,55), as conﬁrmed
by predicted targets functions in carbohydrate metabolism
(Figure 4f).
Regulators of PB-mediated long-term liver gene
expression changes are downstream of CAR signaling
In order to assess the importance of CAR in the livers in
physiological conditions, i.e. without PB treatment and to
identify to what extent the response to PB treatment is
downstream of CAR activation, we made use of gene
expression proﬁles from CAR WT and KO mice (19).
We ﬁrst identiﬁed regulators that are downstream of
CAR under physiological conditions by comparing motif
activities between non-treated CAR KO and WT samples
(Figure 2a provides a schematic representation of all motif
activity contrasts that we calculated). Only ﬁve motifs
were signiﬁcantly downregulated in their activity upon
CAR deletion (Supplementary Table S2 provides a full
list). To assess the CAR dependence of the regulatory
motif changes mediated by PB treatment, we compared
regulatory motifs that are perturbed in activity upon PB
treatment in WT animals, with motifs that are perturbed
upon PB treatment in CAR KO animals. Strikingly, of the
23 motifs dysregulated upon PB treatment in WT mice,
none was dysregulated in KO mice, indicating that all
regulators of PB-mediated gene expression changes
at Day 161 are downstream of CAR signaling
(Supplementary Table S2). This result is in line with
previous studies where CAR was shown to be critical for
both the acute (20) and chronic (19) transcriptional
response to PB treatment. These results are further con-
ﬁrmed by an SVD analysis (Supplementary Results and
Supplementary Figure S6), which shows that the major
source of motif activity changes in these liver samples is
the CAR-dependent liver response to PB treatment. In
summary, it is highly likely that all motif activity
changes observed in the early response time course also
depend on CAR activation.
Identiﬁcation of speciﬁc regulators of promoted tumors
involved in early PB-mediated response
Our analysis above has focused on regulators that are per-
turbed during the ﬁrst 3 months of PB treatment, whereas
it takes several more months for tumors to be detected at
the histopathologic level (21). We next investigated which
regulators have different activities in the end-stage
tumors that are observed after 8 months of treatment, as
compared with their surrounding tissue (Figure 2b). We
hypothesized that motifs perturbed both in the early
response as well in the end-stage tumors may likely be
involved in the process of tumor formation. Moreover,
we distinguished ‘promoted’ tumors, which are
characterized by mutations that cause constitutive activa-
tion of b-catenin, from ‘non-promoted’ tumors that are
characterized by mutations in Ha-ras activation. Motifs
that are perturbed in promoted tumors, but not in
Ha-ras tumors, are prime candidates for involvement in
the non-genotoxic tumor promotion.
We ﬁnd eight motifs that are perturbed in both
promoted and non-promoted tumors (Supplementary
Table S3). Half of these were also associated with one of
the singular vectors of the early PB treatment time course.
In particular, the motif NR5A1,2 was associated with
singular vector 4, showing a downregulation in the PB-
treated animals in the third month of the time course, is
also downregulated in the end-stage tumors. Predicted
targets for NR5A1,2 are involved in several known meta-
bolic functions of the liver [oxido-reduction processes,
peroxisome proliferator-activated receptor (PPAR) signal-
ing, and energy metabolism] (55), consistent with target
functions at the early time points, indicating that
NR5A1,2 downregulation is associated with hepatocyte
loss of function (Figure 5a). Furthermore, our analysis
identiﬁes SOX{8,9,10} as a regulator of cell proliferation
in both promoted and non-promoted tumors (Figure 5a).
As these motifs are perturbed in both promoted and non-
promoted tumors, they likely regulate genes involved in
general liver tumor biology and are presumably not
relevant for the speciﬁc process of non-genotoxic tumor
promotion.
Seven motifs were dysregulated in promoted tumors
only (Supplementary Table S4). Strikingly, all but one of
these motifs were associated with one of the singular
vectors of the early PB treatment time course. In particu-
lar, the E2F motif, which we found to be a positive regu-
lator of both the postnatal liver growth and the transient
PB-mediated mitogenic response, is here observed to be
upregulated only in promoted tumors (zpromoted tum: ¼ 2:6),
showing no signiﬁcant perturbation in the non-promoted
tumors (znonpromoted tum: ¼ 0:3). Importantly, E2F1,
E2F2 and E2F8, previously identiﬁed as strong candidate
regulators of early PB-mediated transient hyperplastic
response, display similar positive correlation between
their gene expression and the motif activity in the tumor
(Supplementary Figure S3a and Supplementary Table S5).
Notably, the cellular functions regulated by SOX{8,9,10}
and E2F at tumor stage (Figure 5a and b) suggests that
these motifs have distinct regulatory effects on cell prolif-
eration; while SOX{8,9,10} regulates mitosis, E2F targets
speciﬁcally regulate DNA replication (Supplementary
Figure S2).
The ZFP161 motif, which we found to negatively
regulate transcriptional repressors of the cell cycle in
the early stages of PB treatment, also displays signiﬁ-
cant decrease in activity in promoted tumors
(zpromoted tum: ¼ 1:6), but not in non-promoted tumors
(znonpromoted tum: ¼ 0:7) (Figure 5b). Interestingly, these
results suggest that similar regulatory mechanisms,
involving E2F and ZPF161, are responsible for the prolif-
eration that occurs transiently immediately upon PB treat-
ment as well as the proliferation in promoted tumors.
Moreover, this upregulation of proliferation, which
might involve the release of speciﬁc cell-cycle check-
points, is clearly distinct from the regulatory mechanism
responsible for upregulation of proliferation in the non-
promoted tumors.
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Another motif speciﬁcally upregulated in promoted
tumors is NFE2 (zpromoted tum: ¼ 2:5 versus
znonpromoted tum: ¼ 1:4). Furthermore targets of NFE2
that already showed upregulation at the early stage, such
as several members of the protease family and oxidative
stress response, e.g. Aox1, Acox2, Srxn1 andMocos, show
continued activation in the promoted tumors (Figure 5b).
Finally, our analysis revealed a signiﬁcant decrease in
activity of the motif bound by ESR1 in promoted tumors
only (zpromoted tum: ¼ 2:9 versus znonpromoted tum: ¼ 0:5).
Moreover, our analysis shows ESR1 regulation of genes
involved in anatomical structure morphogenesis/tissue re-
modeling (genes, e.g. coding for collagen and ﬁbronectin)
that are progressively downregulated upon PB treatment
and remain repressed at the tumor stage (Figure 5b). We
also performed an SVD analysis of the activity matrix of
this dataset (Supplementary Results and Supplementary
Figure S7). The analysis identiﬁed the most signiﬁcant
singular component with regulators of promoted tumors
that largely overlap those identiﬁed by differential motif
activity analysis. The second singular component
identiﬁed a number of regulators of liver tumorigenesis.
Interestingly, these motifs were not identiﬁed by differen-
tial motif activity analysis, suggesting that SVD analysis
can identify a signiﬁcant effect of a set of motifs even when
the differential activity of each motif is not signiﬁcant by
itself.
Early regulators of liver tumor promotion downstream of
b-catenin signaling
It has been established that liver tumor promotion by PB
requires functional b-catenin (56) and promoted tumors
are characterized by mutations that cause constitutive ac-
tivation of b-catenin. However, it remains unclear how PB
promotes the outgrowth of pre-existing b-catenin
activated cells. The ability for b-catenin to physically
interact with various co-factors and nuclear receptors
(57,58) suggests that the predicted regulators of PB-
mediated liver tumor promotion may interact with the
b-catenin pathway.
We thus investigated which regulators are downstream
of b-catenin under physiological conditions by comparing
motif activities in non-treated WT and b-catenin KO cells
(Figure 2c). This analysis showed massive changes in regu-
latory activities upon KO of b-catenin, with as many as
33 motifs signiﬁcantly perturbed in their activity
(Supplementary Table S5). Note that this analysis success-
fully retrieved known co-factors of b-catenin such as the
Tcf7-Lef1 motif, whose activity decreases strongly upon
b-catenin KO (zkowt ¼ 3:2). Furthermore, two of the
previously identiﬁed regulators of liver tumor promotion,
i.e. E2F (zkowt ¼ 2:0) and NFE2 (zkowt ¼ 2:2), were
negatively modulated upon b-catenin KO, whereas ESR1
(zkowt ¼ 2:9) was positively modulated. These ﬁndings
support the hypothesis of a positive interaction between
E2F/NFE2 and the b-catenin signaling pathway. The
strong positive correlation between ESR1 gene expression
and motif activity in both this study and the tumor study
(Supplementary Figure S3 and Supplementary Table S6)
supports a negative interaction between the b-catenin sig-
naling pathway and ESR1 in liver, potentially through
direct repression of target gene by b-catenin.
DISCUSSION
Here we describe a novel bioinformatics approach for the
automated identiﬁcation of independent transcription
regulatory programs within a complex in vivo tissue envir-
onment. Using well-characterized mouse mechanistic
models for non-genotoxic hepatocarcinogeneis, we were
able to successfully infer the contributions of key
(a)
(b)
Figure 5. Regulators of liver tumorigenesis and tumor promotion.
(a) Activities of two regulators that are dysregulated in both
promoted and non-promoted tumors. (b) Activities of four regulators
that are speciﬁcally dysregulated in promoted tumors. For each regu-
lator, the activities in the tumor and surrounding normal tissue are
indicated by black and turquoise points, respectively. A z-value quan-
tifying the overall signiﬁcance of the motif in tumor dataset is indicated
below each motif’s name. A selection of biological pathways and func-
tional categories (Gene Ontology or KEGG) enriched among tar-
get genes of these motifs are shown on the right of each activity
proﬁle. The height of each bar corresponds to the signiﬁcance
[ log10ðP valueÞ] of the enrichment. Differences in activity between
the tumor and surrounding tissues that are signiﬁcant are indicated by
an asterisk (jzact:j  1:5).
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regulators of phenobarbital-mediated xenobiotic re-
sponses, tumor promotion and end-stage tumors as well
as assess their dependence on the CAR and b-catenin
signaling pathways.
Motif activity response analysis, which models observed
gene expression patterns in terms of computationally pre-
dicted TF-binding sites, has been speciﬁcally designed to
identify the key regulators responsible for the observed
gene expression dynamics. One of its strengths is that
MARA does not rely directly on the mRNA expression
of the TFs, but instead infers the activities of regulators
from the expression of their predicted target genes.
Consequently, MARA can easily identify changes in
motif activities that are due to post-translational modiﬁ-
cations, changes in cellular localization or interactions
with co-factors. This is speciﬁcally relevant for our
model system in which PB indirectly triggers changes
in gene expression via EGFR signaling-mediated post-
translational modiﬁcation and nuclear translocation of
the TF CAR (15,16).
A major challenge in the analysis of the complicated
in vivo systems such as the one we study here, is that the
observed genome-wide expression changes result from
multiple biological pathways dynamically changing in
parallel. Consequently, even when MARA allows us to
infer the regulatory activities of key TFs across the
samples, it may be challenging to identify the independent
biological processes that these regulators contribute to
and how each regulator is contributing to each process.
To address this, we here developed a new analysis
approach based on SVD that decomposes the entire
matrix of motif activities across all samples and identiﬁes
the major mutually independent activity proﬁles.
Our results show that this approach successfully
identiﬁes the major biological pathways underlying the
response to PB treatment and it furthermore allows us
to identify how the key regulators are contributing to
each of these pathways. We identiﬁed the roles of E2F
and ZFP161 in the regulation of cell proliferation in
both the early transient mitogenic response and speciﬁc-
ally in promoted tumors. We identiﬁed ESR1 as a key
regulator of establishing a tumor-prone environment and
we identiﬁed NFE2 as a key regulator of the sustained
xenobiotic response. Figure 6 schematically summarizes
these key ﬁndings, showing both the overall picture
that emerges of the biological processes involved in PB-
mediated tumor promotion (Figure 6a) as well as the key
regulators that we identiﬁed and their role in the various
processes (Figure 6b).
In the next sections we discuss these key ﬁndings, put
them into context of relevant available literature and put
forward concrete hypotheses for the biological mechan-
isms involved in these regulatory processes. Finally,
where possible, we also discuss pieces of supporting
evidence for the hypotheses we put forward.
E2F as a positive regulator of the PB-mediated
proliferative response at both the early and tumor stages
An important aspect of PB-mediated tumor promotion is
the ability of PB to induce a transient mitogenic response
and to cause liver neoplasia upon chronic administration.
However, the exact mechanisms responsible for the exit
from the quiescent state and the re-entry into the cell
cycle remain largely unknown [see (59) for a review].
Our analysis revealed that the regulatory motif bound
(a)
(b)
(e)
(c) (d)
Figure 6. Schematical representation of PB-mediated tumor promo-
tion, as it emerges from our study. (a) Illustration of the PB-
mediated tumor promotion process and the aspects elucidated by the
four experimental studies that we analyze. KO of b-catenin identiﬁes
regulators downstream of b-catenin in physiological conditions (yellow
arrow). This study and previous analyses suggest that all regulatory
effects of PB treatment are downstream of CAR activation (brown
arrow and black circle). This study’s motif activity and SVD analysis
of the early kinetic time course identiﬁed three key biological processes
induced by PB treatment: a transient mitogenic response, which is also
associated with a late resurgence of proliferation (I, red), a sustained
xenobiotic response (II, yellow) and a late response which is likely
involved in establishing a tumor-prone environment (III, blue).
Comparison of promoted and non-promoted tumors identiﬁes motifs
dysregulated in all tumors and in promoted tumors only (gray arrows).
(b–d) Summary of the key regulators of liver tumor promotion
organized according to biological processes (colored boxes matching
the colors of processes I, II and III in panel a) with arrows indicating
regulatory interactions between regulators and on selected target genes.
(b) E2F and ZFP161 regulate PB-mediated hepatocyte proliferation at
the early and promoted tumor stage. E2F is downstream of b-catenin
signaling and likely induces both DNA replication, via upregulation of
E2f1,2 and aborted cytokinesis via upregulation of E2f8 and c-myc.
ZFP161 is likely involved in the G0–G1 transition via transcriptional
repression of transcriptional repressors of cell growth and cell cycle. (c)
NFE2, downstream of b-catenin as well is involved in the sustained
xenobiotic response, upregulating proteasome activity and the oxidative
stress response. (d) PB-mediated suppression of ESR1 activity underlies
development of a tumor-prone environment, most likely through re-
pression of tissue morphogenesis. b-Catenin signaling represses ESR1.
(e) Key regulators involved in tumorigenesis, i.e. dysregulated in both
promoted and non-promoted tumors. Increased SOX{8,9,10} activity
likely regulates hepatocyte mitosis and proliferation via upregulation of
cyclins. Decrease in NR5A1,2 activity is detected after 3 months of PB
treatment and maintained in tumor samples and therefore a good early
indicator of hepatocyte loss-of-function associated with tumorigenesis.
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by the E2F family of TFs is one of the key factors posi-
tively contributing to the early proliferative response upon
PB treatment. In addition, E2F is upregulated in
promoted tumors, but not in non-promoted tumors.
Importantly, the absence of E2F motif modulation in
non-promoted tumors argues against the hypothesis that
the motif is simply reﬂecting increased proliferative
activity. Furthermore, the fact that KO of b-catenin in
physiological conditions leads to downregulation of E2F
activity implies that b-catenin positively regulates E2F
activity (either directly or indirectly) and suggests that
PB-mediated activation of b-catenin may contribute to
the upregulation of E2F activity at the tumor stage.
The plausibility of a role for E2F TFs in PB-mediated
tumor promotion is supported by numerous studies re-
porting a central role of distinct E2F family members in
hepatocellular carcinoma (60,61). More speciﬁcally, PB-
mediated modulation of E2F gene regulation in freshly
isolated hepatocytes has been previously suggested (62).
Here we show a highly speciﬁc upregulation of E2F
activity in promoted tumors and a potential role in
tumor promotion through b-catenin-mediated activation.
The E2F family contains eight different TFs that can
bind to the E2F motif and the MARA analysis does not
directly predict which of these eight TFs is mainly respon-
sible for the activity of the E2F regulatory motif in this
system. However, measurements of motif activity correl-
ation with mRNA expression of the TFs (Supplementary
Figure S4 and Supplementary Table S6) shows that the
expression of E2F1, E2F2 and E2F8 exhibit the most sig-
niﬁcant correlation with E2F motif activity in the time
course and tumor studies. This makes these TFs the
most likely candidates for driving the E2F motif activity,
but it should be noted that motif activity changes do not
necessarily require changes in mRNA levels of the
binding TFs, i.e. the activity change may be due to post-
translational modiﬁcations, nuclear localization, etc. E2F7
and E2F8 have been recently shown to play a key role in
positively regulating hepatocyte polyploidy (63,64).
Interestingly, Myc has been shown to be an additional
positive regulator of polyploidy in hepatocytes (65,66).
Furthermore, both E2f8 and c-myc are signiﬁcantly
upregulated in promoted tumors only and both are pre-
dicted targets of E2F. Given that ligands of nuclear recep-
tors such as PB and TCPOBOP have been shown to cause
liver polyploidization (59,67,68), we propose that both
E2F1 and E2F8 are responsible for the E2F activity
modulation at the tumor stage and that they regulate
distinct cell cycle checkpoints, in particular, regulation
of entry in S-phase for E2F1 and inhibition of cytokinesis
for E2F8 together with Myc (Figure 6b).
ZFP161 as transcriptional repressor involved in the
PB-mediated proliferative response at both the early and
tumor stages
Our analysis revealed a decrease in activity of the motif
bound by ZFP161 (also known as ZF5), i.e. an overall
downregulation of its predicted targets upon PB treatment
contributing to the early transient proliferative response.
In addition, ZFP161 targets are downregulated in
promoted tumors, but not in non-promoted tumors.
Affymetrix gene expression analysis shows that while
ZFP161 is not transcriptionally regulated by PB and its
mRNA expression is not correlated with motif activity
(Supplementary Figure S3), it is clearly expressed in the
liver (log2 e  8:0).
Although ZFP161 has been shown to be preferentially
active in differentiated tissues with little mitotic activity
(69), where it was shown to act as a transcriptional repres-
sor of c-myc (70,71), we here show an increase in ZFP161
transcriptional repression of target genes enriched in tran-
scriptional repressors (i.e. Mxi1 and Klf10), several of
these being negative regulators of cell cycle and cell
growth. Therefore, we hypothesize that ZFP161 partici-
pates in the PB-mediated regulation of quiescent hepato-
cyte G0–G1 transition at both the early and tumor stages,
by repressing negative regulators of cell cycle and positive
regulators of apoptosis (Figure 6b).
The progressive PB-mediated downregulation of ESR1
contributes to establishing a tumor-prone environment
PB-mediated tumorigenesis involves dynamic changes in
tissue composition, and the adaptive response of the liver
to chronic stress eventually leads to the establishment of a
tumor-prone environment. The identiﬁcation of key
factors that contribute to this process could provide
valuable insight into the development of PB-mediated
tumorigenesis. Our analysis identiﬁed ESR1 as a factor
progressively downregulated upon chronic PB exposure,
starting in the third month of PB treatment. In addition,
ESR1 activity is downregulated in promoted tumors, but
not in non-promoted tumors. These two observations
make ESR1 a strong candidate regulator for the process
of establishing a tumor-prone environment. Furthermore,
b-catenin KO in physiological conditions leads to
upregulation of ESR1 activity, implying that b-catenin
represses (directly or indirectly) ESR1. Further supporting
this direct link between b-catenin and ESR1 repression is
the fact that the highest correlations between ESR1
activity and mRNA expression levels are observed in the
b-catenin KO and tumor studies, i.e. precisely those ex-
periments where b-catenin activity is predicted to change
(Supplementary Figure S3). Importantly, a physical inter-
action between b-catenin/TCF-4 and ESR1 has already
been reported in other physiological contexts (72,73).
That ESR1 can have tumor suppressor activity is sup-
ported by various studies (4,74–77). However, here we
propose more speciﬁcally that the progressive suppression
of ESR1 activity from early hyperplastic tissue to cancer
(78) is mediated by PB chronic exposure and is one of the
mechanisms underlying PB-mediated liver tumor promo-
tion due to negative regulation of tissue morphogenesis
(Figure 6d).
NFE2 as a regulator of exacerbated xenobiotic response
associated with promoted tumors
Our analysis revealed that PB treatment causes a constant
upregulation of homeostatic processes via NFE2 activa-
tion of proteasome and oxidative stress biological
processes during the early phases of treatment and that
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this upregulation persists into promoted tumors
(Figure 6c). Of note, NFE2 regulatory activity in homeo-
static processes has been shown in a recent study (49).
This upregulation of NFE2 in tumors compared to the
surrounding tissue is speciﬁc to promoted tumors.
Furthermore, the fact that NFE2 activity is
downregulated upon b-catenin KO in physiological con-
ditions strongly suggests that b-catenin signaling is posi-
tively regulating NFE2 activity. As b-catenin is also
involved in the regulation of drug metabolizing enzymes
in the liver (79–82), we hypothesize that NFE2 and
b-catenin cooperate in regulating genes involved in drug
metabolism and that the xenobiotic response is partly
exacerbated in promoted samples upon constitutive acti-
vation of b-catenin, resulting in further upregulation of
NFE2.
Regulators of liver tumorigenesis
Our analysis identiﬁed several regulators of liver tumori-
genesis (Supplementary Table S3). Interestingly, NR5A1,2
downregulation is observed early in the process of tumor
promotion (after 3 months of PB treatment). Given its
apparent role in hepatocyte liver function regulation
(Supplementary Figure S1) we hypothesize that
NR5A1,2 is associated with hepatocyte loss of function
(Figure 6e). SOX{8,9,10} is an additional regulator of
liver tumorigenesis and our analysis indicates a role in
hepatocyte proliferation. Finally, comparing functional
enrichment between the target genes of SOX{8,9,10} and
E2F at tumor stage revealed that while E2F speciﬁcally
regulates DNA replication (Supplementary Figure S2),
SOX{8,9,10} preferentially targets mitotic genes
(Supplementary Figure S1). These results support our hy-
pothesis that E2F targets cell cycle check points that are
distinct from those shared with other tumors.
Future extensions of the modeling approach
In future work we will aim to address several limitations
of the current modeling approach. First and foremost,
the method is currently limited to inferring the activities
of only those TFs for which sequence speciﬁcities are
known, i.e. roughly 350 of the approximately 1500
mouse TFs. For example, we were not able to predict
CAR motif activity as there is, to our knowledge, no
high quality sequence motif available for CAR. This is
not an intrinsic limitation of the method and as regulatory
motifs for an increasing number of TFs becomes available,
they can easily be incorporated into the method.
Another major limitation of MARA is that it currently
focuses solely on predicted TFBSs in proximal promoters,
ignoring the effects of distal enhancers. Although a
number of combined experimental and computational
methods have been put forward recently that allow
genome-wide mapping of active enhancers [e.g. (83)],
these methods require considerable investment and
enhancer maps are only available for a small set of
selected model systems. As the locations of relevant en-
hancers vary highly across tissues and model systems, suc-
cessful incorporation of enhancers into MARA requires
the availability of enhancer maps for the speciﬁc system
under study.
Most importantly, all the hypotheses discussed in this
work are based on analysis of high-througput data and
future experimental studies will be required to characterize
our inferred TF activities in more detail at the biochemical
level. Such studies may include chromatin immunopre-
cipitation (ChIP) assays on liver tissue from control and
phenobarbital-treated mice.
CONCLUSION
We have demonstrated that by combining motif activity
response analysis with SVD, we are able to automatically
untangle the regulatory activities underlying the perturb-
ation of multiple biological pathways in complex in vivo
systems and derive novel hypotheses regarding the key
regulators and their role in the process. Our analyses
provide novel mechanistic insight for PB-mediated
tumor promotion in the mouse liver, including the identi-
ﬁcation of E2F and ZFP161 as regulators of PB-mediated
hepatocyte proliferation at both early and tumor stages
and progressive PB-mediated suppression of ESR1
activity that may contribute to the development of a
tumor-prone environment. These ﬁndings may also help
identify novel biomarkers for assessing the carcinogenic
potential of xenobiotics.
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